2001
Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies
Mao Q, Ray S, Laeyendecker O, Ticehurst J, Strathdee S, Vlahov D, Thomas D. Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies. Journal Of Virology 2001, 75: 3259-3267. PMID: 11238852, PMCID: PMC114119, DOI: 10.1128/jvi.75.7.3259-3267.2001.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHCV quasispeciesHypervariable region 1HIV seroconversionChronic hepatitis C virus (HCV) infectionE2 hypervariable region 1Hepatitis C virus infectionHuman immunodeficiency virus (HIV) seroconversionRapid HIV disease progressionHepatitis C virus quasispeciesHIV infection altersHIV-associated diseaseChronic HCV infectionC virus infectionHIV disease progressionHCV infectionHCV RNASerum levelsLiver diseaseImmunodeficiency virusDisease progressionRapid progressionVirus infectionNumber of subjectsHCV sequences
2000
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas D, Astemborski J, Rai R, Anania F, Schaeffer M, Galai N, Nolt K, Nelson K, Strathdee S, Johnson L, Laeyendecker O, Boitnott J, Wilson L, Vlahov D. The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors. JAMA 2000, 284: 450-456. PMID: 10904508, DOI: 10.1001/jama.284.4.450.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseInjection drug useHepatitis C virus infectionC virus infectionHuman immunodeficiency virusViral clearanceHCV infectionLiver diseaseDrug usePersistent viremiaVirus infectionCases of ESLDRisk of ESLDCommunity-based prospective cohort studyAntibody-positive test resultPresence of ascitesProspective cohort studyCause of deathUtilization of treatmentMajority of adultsSemiannual visitsCohort studyHCV RNAEsophageal varicesImmunodeficiency virusDeterminants of the Quantity of Hepatitis C Virus RNA
Thomas D, Astemborski J, Vlahov D, Strathdee S, Ray S, Nelson K, Galai N, Nolt K, Laeyendecker O, Todd J. Determinants of the Quantity of Hepatitis C Virus RNA. The Journal Of Infectious Diseases 2000, 181: 844-851. PMID: 10720503, DOI: 10.1086/315314.Peer-Reviewed Original ResearchConceptsHCV RNA levelsHepatitis C virus RNAHIV-negative personsC virus RNAHCV RNARNA levelsLower HCV RNA levelsSerum HCV RNA levelsHepatitis B infectionInjection drug useHuman immunodeficiency virusVirus RNAVirologic factorsB infectionHCV infectionImmunodeficiency virusNeedle sharingBlood levelsPositive personsDrug useYounger ageInfectionEquivalents/Additional researchPerson variabilityScreening for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Individuals
Thio C, Nolt K, Astemborski J, Vlahov D, Nelson K, Thomas D. Screening for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Individuals. Journal Of Clinical Microbiology 2000, 38: 575-577. PMID: 10655348, PMCID: PMC86151, DOI: 10.1128/jcm.38.2.575-577.2000.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHCV RNANegative participantsHepatitis C virus antibody testHuman immunodeficiency virus-infected individualsHepatitis C virus screeningThird-generation enzyme immunoassayHIV-negative participantsVirus-infected individualsHepatitis C virusInjection drug usersThird-generation assaysCOBAS AMPLICOR systemFalse-negative testsThird-generation testsFalse-negative resultsAcute infectionHIV infectionImmunodeficiency virusC virusAntibody formationAntibody testHCVVirus screeningAmplicor system
1999
Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection
Villano S, Vlahov D, Nelson K, Cohn S, Thomas D. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection. Hepatology 1999, 29: 908-914. PMID: 10051497, DOI: 10.1002/hep.510290311.Peer-Reviewed Original ResearchConceptsRecombinant immunoblot assayHCV RNAAcute infectionViral clearanceAcute hepatitis C virus (HCV) infectionAcute hepatitis C infectionHepatitis C virus infectionPersistence of viremiaAcute HCV infectionAcute hepatitis CC virus infectionHepatitis C infectionTime of seroconversionPeak viral titersHealth care providersSingle laboratory testIllicit drug useHCV seroconversionC infectionHCV infectionHepatitis CPersistent viremiaClinical featuresHCV subtypesPolymerase chain reaction
1995
Correlates of Hepatitis C Virus Infections among Injection Drug Users
Thomas D, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson K. Correlates of Hepatitis C Virus Infections among Injection Drug Users. Medicine 1995, 74: 212-220. PMID: 7623656, DOI: 10.1097/00005792-199507000-00005.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis C virus infectionC virus infectionHuman immunodeficiency virusHCV infectionDrug usersVirus infectionMajority of HCVYears of injectingLong-term drug usersHCV RNASerologic evidenceImmunodeficiency virusBloodborne pathogensInjection drugsViral persistenceImmune responsePersistent infectionHigh riskHCVDrug useBiologic basisStudy participantsInfectionIllicit drugs